This is a 14 month study of an oral agent to be used in the treatment of Alzheimer's disease. It is a double-blind study of 4 doses of Lazabemide compared to placebo (12.5, 25, 50 or 100mgm BID). Safety and efficacy will be evaluated in patients with mild to moderate Alzheimer's disease.
Showing the most recent 10 out of 1103 publications